GINGERA MIDLIFE, UNDERSTOOD
← The reading room
Hormones & treatment · 27 MIN READ

Tablets, patches and long-acting injections: reading the evidence behind generic-medicine evaluation

Full original restored

A complete archive article on dosage forms, generic-medicine evaluation and questions for follow-up, with separate notes on Chinese regulatory terminology, product differences and unverified archive estimates.

Editorial image
In this article
Complete manuscript restored from the archive, with a full English translation. Original medical claims have been preserved for review; medical and regional terminology review remain pending. This is educational reading, not individual medical advice.
This complete September 2026 production manuscript awaits clinical, pharmaceutical and regional regulatory review. References to 'China' mean mainland China; its consistency-evaluation terminology is not identical to US therapeutic-equivalence determinations or substitution rules elsewhere. Archive claims about methodological maturity, first-publication dates, official quotations, the 13-manufacturer nifedipine study, 3.6%/4.4%/98% statistics, microsphere approvals, suppliers and processing temperatures lack item-level verifiable citations and remain independently unconfirmed. They cannot establish superiority or inferiority of marketed products or companies. Not finding public guidance does not establish that regulators lack assessment methods or that authorised products are unsafe. The f2 method has conditions of applicability and alone does not establish clinical equivalence; modified-release products do not all aim for perfectly constant release. Transdermal estradiol usually delivers systemic treatment and must not be conflated with locally acting topical medicines. Vaginal products can have local or systemic effects; absorption and equivalence requirements depend on the product, so low systemic absorption cannot be assumed for every vaginal medicine. Microspheres, implants and other long-acting formulations are distinct; some archive classifications and approval histories, including goserelin, require verification. Injection intervals, indications, duration limits, add-back regimens, age restrictions, 4%–6% bone-density changes and recovery timelines cannot be generalised to all GnRH agonists: consult the locally approved product information and a qualified professional. Complete bone-density recovery is not guaranteed. The pharmacy narrative is not an independently verified case, and its application sites and replacement intervals are not directions for use. Do not stop medicines, switch manufacturers, alter doses or delay care because of this article. Contact a local clinician or pharmacist promptly about unusual effects, and use local emergency services for emergencies. The closing requests for comments and likes are archive wording; do not post medicine lists, medical records or identifiable health details publicly. Seven original images, including charts, are withheld pending rights verification, retaining their positions and captions; those captions do not describe data visible in the notices. The independent landscape cover is illustrative. The English translation is complete, while Taiwan/Hong Kong versions use character conversion; professional review is pending for all versions.

Informed choices about medicines · Dosage forms

A tablet, a patch, an injection of microspheres:
the same label, "passed consistency evaluation",
does not mean the same technical challenge

The same phrase, when applied to an ordinary tablet, is supported by more than a decade of real-world data. Applied to modified-release tablets, transdermal patches, vaginal medicines or long-acting microspheres, the evidence underneath is noticeably thinner. For one dosage form, a regulatory document itself states that "there is currently no mature research method recognised by regulatory authorities domestically and internationally". The question is not whether medicines made in China are good. It is that the depth of verification behind those words differs between dosage forms. Understanding this helps you know which extra question to ask.

Original image withheld pending rights verification

The same molecule presents entirely different challenges when made into a tablet, a patch or an injection lasting a month.

▍The conclusions first

First, "the same ingredient" covers less than most people assume. Making the same molecule into an immediate-release tablet, a modified-release tablet, a patch, a vaginal gel or long-acting microspheres involves entirely different problems. The technical challenges are not on the same scale.

Second, the depth of verification behind "passed consistency evaluation" therefore also varies by dosage form. Ordinary tablets have substantial regulatory data and real-world research behind them. For modified-release products, transdermal patches and vaginal medicines, the methodology itself has only gradually been filled in over recent years.

Third, a particularly striking gap concerns dosage forms commonly used in gynaecology. China has no formally issued bioequivalence guidance for vaginal medicines such as tablets, suppositories, gels and rings. The regulator's own wording is that "there is currently no mature research method recognised by regulatory authorities domestically and internationally".

Fourth, read this sentence all the way through: generic medicines that have passed regulatory review and been legally authorised for marketing can be used with confidence as prescribed. Multiple large studies and regulatory conclusions support this. This article discusses differences in the depth of verification between dosage forms; it does not question the safety of any particular company or product.

Fifth, "passing evaluation" is not a one-off matter. The batches submitted with an application and those commercially manufactured over the following decades are two different things. Regulatory discussion calls these "two kinds of consistency". What you need to know is which dosage form is in your medicine box, and which additional question to ask.

CHAPTER 01 At the pharmacy counter, she was not really asking, "Is there one made in China?"

Three or four people were waiting at a gynaecology clinic's pharmacy counter. When a woman in her forties reached the front, she handed over her prescription.

The pharmacist gave her a small box of patches rather than tablets: a thin patch to apply to the abdomen or buttocks and replace every few days. She took it, turned the box over and read the wording on the back, line by line, stopping at one field.

She looked up and asked, "Is there one made in China?"

The pharmacist said there was.

She paused, then asked, "Can I switch? Isn't the ingredient the same?"

"The ingredient is the same," the pharmacist replied.

That was true. The molecule is indeed the same in an imported product and one made in China. But what she really wanted to know was something else, and she did not yet have the words to ask it: is making a patch that sits on the skin and delivers a medicine steadily over dozens of hours the same kind of challenge as making a tablet that dissolves after swallowing?

Other people were waiting. She said "Oh" and left. The question had not been answered at the counter, and it was not one that could easily be answered there. This article aims to lay it out: not to say which product is better, but to clarify what the statement "the ingredient is the same" actually guarantees across different dosage forms.

CHAPTER 02 First, undo an assumption: a tablet is not simply powder pressed into a disc

Many people carry a simplified model: a medicine is its active ingredient, while making it into a tablet, capsule or patch merely changes how it is taken. If the active ingredient is identical, the effects and safety should be identical too.

That model is half right. The active ingredient is central, but delivering it into the body is a separate field of study: pharmaceutical formulation. The same molecule in different dosage forms can enter the body at very different speeds, sites, peak levels and durations. These differences are precisely where the divide between easier and harder-to-reproduce products lies.

The first hurdle: many medicines will not readily dissolve

For a medicine to work, it must first dissolve and be absorbed. Yet a substantial proportion of drug molecules are inherently poorly soluble. Pharmaceutics divides them into four categories according to solubility and permeability; the two low-solubility categories are called BCS classes II and IV.

How common are they? A frequently quoted estimate is "around 40% of marketed medicines and 70%–90% of molecules in development". One qualification matters: this is an estimate repeatedly cited in review literature, not a statistic from a regulatory authority. Definitions differ between sources, with some giving "around 30%–40% of marketed medicines". It is enough to show that such medicines are common, but should not be treated as a precise finding.

To make poorly soluble drugs into formulations that can be absorbed, the industry has developed several technological approaches, each with its own manufacturing challenges:

Technological approach The problem it addresses Challenges in industrial production
Amorphous solid dispersions Change the drug from a crystalline to an amorphous state, substantially increasing solubility Hot-melt extrusion is temperature-sensitive; spray drying brings residual-solvent and moisture-absorption issues; moisture lowers the system's softening temperature and can trigger recrystallisation
Nanocrystals / nanosuspensions Reduce particles to the nanoscale to improve dissolution through greater surface area Particle-size control and long-term stability; homogenisation at scale
Lipid-based delivery Use a lipid system to help carry the drug into absorption Complex digestion in the body and difficulty maintaining batch consistency
Cyclodextrin inclusion / salt formation / co-crystals Enclose the drug with excipients or alter its crystal form Limited applicability and limits on the increase in solubility

Note: these are established formulation approaches, summarised to illustrate the technical range involved in making the same molecule in different ways. They do not refer to any particular product.

One easily overlooked detail is temperature. Hot-melt extrusion equipment has an upper temperature limit of approximately 220–250°C; that is the equipment's limit. The usable processing window for common pharmaceutical polymers is much narrower, roughly 150–200°C, and some polymers begin degrading around 190–200°C. In other words, whether a product can be made often depends less on the principle than on whether that narrow temperature window allows uniform mixing without damaging the medicine or its excipients.

Original image withheld pending rights verification

From left to right: an ordinary tablet, a transdermal patch and a small pile of microspheres. The problems these three products must solve differ markedly in difficulty.

For these processes, moisture can be an even greater concern than temperature. The amorphous state is thermodynamically unstable; it persists because a carrier holds it "frozen" in place. Once moisture is absorbed, the system's softening temperature falls, molecules regain mobility and crystals may gradually form again: solubility falls back, effectively undoing the formulation work. Producing a formulation in a laboratory does not mean it can be produced in a factory; achieving it in a dry northern climate does not mean it will remain stable in humid storage conditions in the south.

The second hurdle: making release slow is much harder than making it fast

Controlling release is more difficult than improving solubility.

An ordinary tablet has a simple goal: dissolve and be absorbed promptly after swallowing. Sustained- and controlled-release formulations aim for the opposite: release the drug steadily over a dozen or more hours, neither too quickly, which can raise blood concentrations and adverse effects, nor too slowly, which can leave concentrations below effective levels.

To assess whether release profiles are alike, the industry uses a similarity factor, f2. Dissolution profiles for the generic and reference products are compared in the same media; an f2 value between 50 and 100 is generally considered similar. This rule appears in China's 2015 technical guidance on dissolution testing for ordinary oral solid dosage forms, alongside guidance on measuring and comparing dissolution profiles. The approach is internationally established. The question is not the method itself, but how far similarity outside the body can represent equivalence inside it.

A second tool is in vitro–in vivo correlation, or IVIVC. The Guidance on Sustained-release, Controlled-release and Delayed-release Preparations, general chapter 9013, in Volume IV of the 2020 Chinese Pharmacopoeia describes several correlation approaches and explicitly calls for IVIVC studies for sustained- and controlled-release formulations. A common confusion needs correcting: the online claim that "9013 is the dissolution test" mixes up the chapter numbers. The dissolution test is general chapter 0931. The familiar "Level A, B and C correlations" in pharmaceutics textbooks are US Pharmacopoeia and FDA terminology; the Chinese Pharmacopoeia uses the terms point-to-point correlation, statistical-moment correlation and single-point correlation.

Beyond the rules is another practical factor: food. Bioequivalence studies of oral modified-release products are recommended under both fasting and fed conditions. China's 2022 guidance on clinical pharmacokinetic studies of modified-release formulations specifies a high-fat, high-calorie test meal, with about half the calories from fat and total energy on the order of 800–1,000 kilocalories. Release from these formulations is particularly sensitive to gastrointestinal conditions: whether food is present and how quickly the stomach empties can alter the release pattern.

✓ A specific example: 13 companies, four media, none judged similar

A study published in a Chinese journal compared sustained-release nifedipine tablets from 13 companies with a reference product in four different dissolution media. Its conclusion was that none were similar. Another study reported an f2 value below 50 for a nifedipine sustained-release tablet II product.

This shows how broad the term "sustained-release tablet" is: products made by different companies can have release behaviour different enough to fail the similarity criterion. But another point also matters: the differences were detected, showing that the method was working. Whether differences exist and whether there is a way to detect them are separate questions. The latter is the point here: tools are available for oral sustained- and controlled-release dosage forms.

The other half must be stated openly: publicly available statistics on products rejected because their release profiles failed requirements were not found. Regulators publish approval totals in annual review reports; the 2025 report, for example, gave cumulative numbers of approvals and product types. They do not classify rejections by dosage form and reason. Public data therefore cannot currently answer how many products in these categories were held back because of release profiles. Not finding public data is itself a fact. It means nobody should rush to a conclusion on this point.

CHAPTER 03 Excipients and impurities: the decisive factor is often not the active ingredient

Most discussion of formulation stops at the active ingredient. In a pharmaceutical factory, however, the decisive factor is often not the molecule but the materials surrounding it.

Excipients are not merely fillers

In modified-release products, solid dispersions and microspheres, excipients have functional roles. They determine how quickly and where a drug is released and whether it remains stable in storage. Even within the same excipient class, differences in grade, particle size or viscosity change release behaviour. This is among the most time-consuming parts of formulation and process research.

Supply of these key excipients is highly concentrated. A cellulose-ester carrier class used in amorphous solid dispersions is supplied mainly by a small number of companies, including Shin-Etsu in Japan and Dow in the United States. Two other commonly used solubility-enhancing carriers are brands from the same German company. The essential microsphere carrier, poly(lactic-co-glycolic acid), or PLGA, also comes mainly from a few international suppliers.

Are these advanced functional excipients manufactured in China, and what proportion is domestically supplied? This is an important question, but the answer is that no authoritative quantitative data were found within this search's scope. The answer is neither "very low" nor "very high": there are no statistics suitable for citation. Available information consists largely of market-share reports from commercial research firms, with inconsistent definitions that cannot support a firm judgement. The question can only be identified honestly, without inference.

By contrast, another issue has a complete public record and is highly illustrative.

Impurities: from a voluntary report to an entire set of rules

In July 2018, a Chinese active-ingredient manufacturer voluntarily reported to regulators that N-nitrosodimethylamine, or NDMA, had been detected in a batch of valsartan active ingredient it manufactured and exported. NDMA is a nitrosamine impurity. Nitrosamines have shown carcinogenicity in animal studies. Its presence did not mean something had been deliberately added: the manufacturing process itself can generate it under certain conditions.

The response was documented in full:

Original image withheld pending rights verification

Figure 1 | From a company's voluntary report to limits, revision of national standards and a full set of research guidance took less than two years. The system moved faster than many people might assume. Note: different official channels record the August 2018 public-notice date as either 17 or 20 August; only the month is shown here.

After these four steps, nitrosamines were no longer simply one incident at one company. They became a question the industry had to address batch by batch. Other countries subsequently found similar impurities in other products, showing a risk requiring systematic management in synthesis processes rather than an isolated event.

The accompanying rules also require detailed comparisons. Technical requirements for consistency evaluation of injections call for comprehensive quality comparisons between the applicant's product and the reference, including impurity-profile comparisons: not just the total quantity but which impurities are present and how much of each. Reviewers from China's Center for Drug Evaluation explained this more directly in a professional journal: in principle, an impurity should not exceed the limit specified for the reference product.

⚠ What this section should not be taken to mean

The discussion of excipients and impurities concerns the difficulty of consistently manufacturing a medicine in its intended form. It does not mean that reliance on imported excipients makes a medicine problematic, nor does it mean that a class of medicines in which impurities were once detected should not be taken.

The real lesson of the nitrosamine episode is the reverse: problems were detected, characterised, limited and incorporated into rules, showing regulation at work. The areas that deserve attention are those nobody has examined. Where might those be? That is the subject of the next section.

CHAPTER 04 Which dosage forms already have a yardstick, and which do not?

Judging whether a generic and an originator are equivalent first requires an accepted assessment method. If a method exists, one can discuss how accurately it measures equivalence. Without one, another route is needed.

The differences between dosage forms on this point can be striking.

Immediate-release oral products: the most established yardstick

Ordinary tablets and capsules have the clearest rules. For eligible highly soluble drugs, human bioequivalence studies can even be waived when dissolution-profile comparison requirements are met. China formally implemented an internationally harmonised version of this solubility–permeability-based waiver approach in 2021. The review authority also clarified that it would no longer issue a separate list of products eligible for waivers: applicants can request a waiver directly when the conditions are met.

Oral sustained- and controlled-release products: a yardstick is available

As discussed above, dissolution-profile similarity using f2, IVIVC and fasting/fed conditions provide three tools. The nifedipine comparison involving 13 companies used these tools.

Transdermal patches: quality guidance came before clinical assessment guidance

Transdermal patches illustrate the issue well. In 2020, China issued technical guidance on pharmaceutical quality studies of chemical generic transdermal patches. As the name indicates, it addresses pharmaceutical quality studies: formulation and processes, active ingredients, excipients and materials, quality comparisons covering in vitro release, in vitro permeation, adhesion and residual drug, and stability. In other words, it addressed how to make a patch and establish its quality, but not how to show equivalence to the originator in patients.

The clinical side became systematic only after 2022 guidance on clinical trials of locally administered, locally acting medicines. In January 2026, further clinical guidance specifically addressing adhesion, irritation and sensitisation of transdermal and topical delivery systems took effect. Questions such as whether a patch adheres adequately or causes skin allergy therefore acquired a dedicated technical document only in 2026.

International comparisons illustrate the detail involved. The US FDA's product-specific guidance for estradiol transdermal patches calls for a set of studies: a pharmacokinetic bioequivalence study in postmenopausal women, with 84 hours of application and both baseline-corrected and uncorrected data; an adhesion study; and a skin-irritation study. Some requirements can be waived for lower strengths.

Topical semisolids: the yardstick arrived in 2025

Equivalence is harder to assess for ointments, creams and gels applied to the skin for local effects. As the drug mainly does not enter the blood, measuring blood concentrations is not useful. In vitro release testing, IVRT, and in vitro permeation testing, IVPT, have been developed internationally for this purpose.

China's first technical guidance on IVRT/IVPT studies was issued in 2025, as Notice No. 22 of 2025, effective on publication. Its scope is explicit: semisolids applied to the skin or delivered through it for local effects, namely ointments, creams and gels. It applies where an individual drug's guidance calls for it.

In other words, before 2025 China had no dedicated methodological document for this class, and this document extends only to semisolids. A further note: channels give either 29 May or 20 June as its publication date; the Center for Drug Evaluation's notice date should take precedence.

Vaginal dosage forms: the yardstick is still missing

This brings us to a particularly important gap.

Vaginal tablets, suppositories, gels and rings are common in gynaecology. They share local action and low systemic absorption, placing them in a blind spot for the standard blood-concentration approach. Does China have dedicated bioequivalence guidance for vaginal formulations?

⚠ An official statement that should be quoted verbatim

China's Center for Drug Evaluation has publicly addressed such questions. One sentence states: "There is currently no mature research method recognised by regulatory authorities domestically and internationally, and there have been no cases in which such research has supported waiving a clinical equivalence trial using the reference product as a comparator."

In other words, the issue is not simply an imperfect method, but the absence of a method accepted by all sides. The regulator previously sought public comments on technical evaluation requirements for vaginal tablets and suppositories, but no formally issued final version was found within the search's scope.

What happens in practice? Without an accepted waiver method, vaginal tablets and suppositories generally have to follow a clinical-endpoint equivalence trial against the reference product: directly compare outcomes in patients. Products with systemic absorption additionally require pharmacokinetic research. Vaginal rings rely primarily on pharmacokinetic studies.

An immediate qualification is needed to prevent misunderstanding: international practice is not uniform, and it is not uniformly absent. The US FDA has issued product-specific guidance for individual vaginal products. For example, metronidazole vaginal gel and clindamycin phosphate vaginal gel can use in vitro bioequivalence together with formulation composition and critical-quality-attribute characterisation, without necessarily requiring clinical-endpoint trials. Estradiol vaginal rings and inserts use a pharmacokinetic approach. This shows that a route is possible, although relatively few products have established it, and China was not the first to set those rules.

Original image withheld pending rights verification

Figure 2 | Behind the same phrase, "passed consistency evaluation", are assessment methods with different degrees of maturity. Read this chart as a relative comparison, not a verdict on any class of medicine.

CHAPTER 05 The most difficult category: microspheres that must release steadily over many days

Asked to name the dosage form with the greatest technical difficulty, many people would choose long-acting injectable microspheres.

What are microspheres? A drug is dispersed within biodegradable polymer material and formed into spherical particles tens of micrometres across, suspended in liquid and injected. As the material gradually degrades, the drug is released slowly. One injection can last a month, three months or longer.

Several challenges concentrate here. First is burst release: release that is too rapid in the first week can raise blood concentrations and adverse effects. Second is stable long-term release: the rate must remain steady over many days, rather than starting loosely and tightening later. Third is the material itself, including PLGA mentioned above. Fourth is scaling up sterile manufacture: microspheres are sterile injectables, and moving from laboratory scale to a production line requires specialist equipment and process experience. Fifth is standards and testing: even measuring whether release is uniform requires developing a method.

Original image withheld pending rights verification

What a long-acting microsphere injection looks like: medicine is enclosed in biodegradable polymer particles, whose gradual degradation releases the drug. The challenge is not simply making it, but achieving steady release over many days afterwards.

These dosage forms matter more in gynaecology and reproductive medicine than many people realise. Common gonadotropin-releasing hormone agonist microspheres, for example, are used for endometriosis, preoperative preparation for uterine fibroids and downregulation in assisted reproduction. Typical use involves monthly injections for several doses. For common strengths, this generally means one injection every 28 days, starting early in the menstrual cycle; total treatment for endometriosis generally does not exceed 12 months, while preoperative fibroid treatment generally does not exceed three months.

A trade-off must be explained. By suppressing sex-hormone secretion, these medicines produce a state resembling medication-induced menopause. Common effects include hot flashes, sweating, mood changes and loss of bone mineral density. Over a six-month course, for example, density at predominantly trabecular-bone sites such as the lumbar spine falls by around 4%–6%. After treatment stops, most people experience partial to complete recovery, usually over six to 24 months, with considerable individual variation. This is why guidance recommends an add-back regimen, providing small amounts of sex hormones to counter bone loss, if prolonged treatment is necessary, and explicitly does not recommend use below age 16.

✓ An improving picture: these medicines are not impossible to reproduce

Public information retrieved suggests that domestic production of long-acting microspheres has advanced noticeably in the past three years:

  • In 2023, China's first domestically manufactured long-acting triptorelin microspheres were authorised, with an endometriosis indication added in 2024.
  • In 2023, the first domestic long-acting octreotide microsphere product was authorised under consistency-evaluation requirements.
  • In 2023, goserelin microspheres were authorised.
  • In 2024, the first leuprorelin microsphere product passed consistency evaluation.
  • In 2025, the first risperidone microsphere product passed consistency evaluation and demonstrated bioequivalence to the originator.

Regulators have also issued draft guidance for public comment on bioequivalence studies of individual microsphere products, including leuprorelin microspheres in October 2023. These use randomised, two-treatment, parallel designs, with endpoints including peak concentration and exposure during different intervals. The gaps in methods and product-specific instructions discussed above are being filled one by one, although the sequence is from harder to easier rather than easier to harder.

CHAPTER 06 Put the evidence on both sides on the table

At this point, omitting the evidence on the other side would be dishonest. Differences in verification depth between dosage forms can easily be misread as proof that generic medicines are unreliable, and that conclusion is not justified.

The evidence supporting substitution with generics is strong

Start with the data. The US FDA analysed bioequivalence data accumulated over 12 years. Compared with originators, generics differed on average by approximately 3.6% in exposure and 4.4% in peak concentration; around 98% of products differed by less than 10%. Those are impressive figures.

Large-scale evidence also addresses clinical outcomes. An analysis of 74 randomised controlled trials found no significant differences in clinical outcomes between generic and originator cardiovascular medicines. China also has real-world studies. Data cited by regulatory and health-insurance authorities in a February 2025 press response about centrally procured medicines included a hospital's amlodipine study reporting comparable effectiveness and safety; related research found no statistically significant difference in anaesthetic dose and blood-glucose target achievement of about 80% in both metformin groups.

Regulators' positions are also clear. China's medicines regulator states in public education that generics granted marketing authorisation after review have consistent quality and efficacy with originators and can substitute for them clinically. The US FDA's official questions and answers similarly state that products judged therapeutically equivalent can be expected to have the same effects when substituted for the originator.

⚠ The scope of that evidence needs to be understood

Most of the data above concern immediate-release oral dosage forms, ordinary tablets and capsules. They answer whether ordinary tablets can be substituted confidently; the answer is clearly yes.

They do not specifically cover modified-release products, transdermal patches, vaginal medicines or long-acting microspheres. The reverse also holds: these dosage forms have not been shown to be inadequate. The current position is thinner evidence, rather than evidence of a problem. That distinction carries the weight of this entire article.

A clear example of an evidence boundary

In a 2007 committee opinion, the American College of Obstetricians and Gynecologists treated FDA-approved generic and brand-name oral contraceptives as clinically equivalent and interchangeable. This is often quoted as saying all gynaecological medicines are the same.

Its scope, however, is explicit: oral contraceptives, in ordinary oral dosage forms. It concerns a tablet swallowed every day, not a skin patch, vaginal gel or intramuscular microsphere injection lasting a month. Extending that statement from oral tablets to every gynaecological dosage form is unsupported. It is also a common substitution in everyday conversation.

✕ Three misunderstandings that are easily waved through

Misunderstanding one: "The ingredient is the same, so the product is the same."
The same molecule, made with different formulations and processes, can enter the body by entirely different routes and patterns. "The same ingredient" answers whether it is the same substance, not whether it performs in the same way.

Misunderstanding two: "Every medicine that passes evaluation must meet the same standard."
The depth of verification behind "passed consistency evaluation" varies by dosage form. Some have more than a decade of real-world data covering tens of millions of uses; for others, accepted assessment methods are still being established. The same label does not contain the same thickness of evidence.

Misunderstanding three: "If differences exist, I should avoid products made in China."
This is the misunderstanding that most needs stopping. The strong evidence above supports using generics as prescribed in the great majority of common dosage forms. Reading ongoing development of a dosage form's methodology as a reason not to use it mistakes a judgement about rules for a judgement about products.

CHAPTER 07 Passing evaluation is not a one-off event: the less visible road afterwards

So far, the question has been whether a medicine can be made. Another dimension is whether it changes after it is made.

Professionals at the Center for Drug Evaluation have drawn a distinction worth remembering: consistency has two layers.

Original image withheld pending rights verification

Figure 3 | Passing evaluation establishes the first stage: the batches studied are equivalent to the originator. The batches we actually take or use belong to the second stage.

The practical significance is that a company passing evaluation does not automatically pass that result on to every batch manufactured for decades afterwards. To protect the second stage, the industry commonly establishes control strategies, fixes critical process parameters through a quality-by-design approach, and handles changes under post-authorisation change requirements. Major changes require renewed approval.

Change also has commercial incentives. Public reporting has quoted industry participants describing cost reductions after evaluation through changing packaging materials, adjusting excipients or extending shelf life. Media have also relayed provincial drug-review and inspection requirements identifying applications for shelf-life extensions without three commercial-scale sample batches. These reports do not establish that change means lower quality: lawful change control exists precisely to permit optimisation within controlled limits. They do, however, identify a point: the road after evaluation also requires continued oversight.

This section uses public information from media and professional journals to describe industry issues worth watching. It makes no allegation against a particular company.

CHAPTER 08 What can you actually do after receiving a medicine?

After the principles and evidence, return to the practical step. What can an ordinary person holding a box of medicine do?

Use with confidence

Immediate-release products such as ordinary tablets and capsules

, provided they are legally authorised following review, have substantial support for use as prescribed from large studies and regulatory conclusions. The word "generic" alone need not make you hesitate.

Take another look

Sustained- and controlled-release tablets, transdermal patches, vaginal medicines, topical semisolids and long-acting injectable microspheres

deserve another two minutes: check whether it is the same strength and the same product from the same manufacturer; turn to the leaflet and read the directions and relevant wording; keep the box and batch number. The point is not that you cannot use them, but that

knowing which category they belong to helps you explain clearly if a problem arises

.

When the manufacturer changes

If the manufacturer of a long-term medicine changes

, mention it at your next follow-up rather than silently adapting.

This particularly matters for release-sensitive products such as modified-release tablets, patches and microspheres

—the change is in the manufacturer, but if the release profile changes, the body experiences something different.

Do not do this yourself

Do not use this article to change or stop medicines, switch manufacturers or alter doses yourself.

Starting, adjusting or stopping a treatment must be decided by the clinician responsible for your care, considering your history, gestational age where relevant, test results and all current medicines.

Three sentences to take to an appointment

Three questions you can ask directly

  • "Which dosage form am I using: an ordinary tablet, a sustained-release tablet, a patch or an injection?" Establish the category first so that later questions have a foundation.
  • "If I switch manufacturers, does my situation need reassessment, and how soon should I have a follow-up?" Leave the decision about switching to your clinician.
  • "How long am I likely to use this medicine, and what should we watch for?" Follow-up timing is part of the plan, especially for long-term use.

If you use long-acting microspheres, another question deserves attention: "Will this affect my bone density? If treatment needs extending, is there a way to offset bone loss?" This is not an unnecessary concern. As discussed, bone density can fall around 4%–6% over six months; most people can recover after stopping, but recovery takes time and varies considerably. Guidance explicitly addresses add-back treatment with prolonged use and recommends against use below age 16. These matters should be explained at prescribing, rather than left for you to discover.

Asking why the relevant wording appears in the leaflet is more useful than judging online whether a medicine is acceptable. A clinician's answer can address your circumstances; an online conclusion cannot.

CHAPTER 09 Back at the pharmacy window

The woman later returned to the clinic.

This time she placed the patches and prescription on the desk, but did not ask whether she could switch to a domestically made product. Instead she asked:

"This one is a patch rather than a tablet. If we change manufacturers, should I have a check-up after a while?"

The clinician looked at her, said that was the right question, took a follow-up sheet from a drawer and wrote two lines.

The exchange took less than two minutes, cost nothing extra and required no technical terminology. She did not understand release profiles and did not need to. What made the difference was that she asked which category her medicine belonged to.

The point throughout this article is not whether medicines made in China are good. That is a separate question with a clear answer. The point is that the words "passed consistency evaluation" rest on different depths of evidence for different dosage forms. You do not need to remember every technical detail; just know whether the medicine in your hand is a tablet, a patch or an injection that lasts a month.

Knowing that tells you which extra question to ask. Once you ask it, leave the remaining judgement to the person across the desk who can see your medical record.

Original image withheld pending rights verification

What changes outcomes is often not learning one more term, but having a follow-up record beside the medicine box.

Which dosage form are you currently using?

Before your next appointment, you can do something simple: take out your current medicines and check whether they are ordinary tablets, sustained-release tablets, patches, topical products or injections. Look at the manufacturer's name and strength on the packaging too, and make a mental note.

👉 Leave a comment about the dosage form you found. If you use patches, sustained-release tablets or regular injections, you are also welcome to share how you remember when follow-up is due. Those experiences can help others.

If someone in your household uses patches or long-term injections, share this article with her. Dosage form is something everyone should know to check.

If you found this useful, tap "Like" and "Reading"

Follow along; this series will continue

Share this with someone taking long-term medicines

Disclaimer: this article provides health education and a summary of medicines-regulation information. It does not constitute individual medical advice, nor does it recommend any particular medicine, brand, manufacturer, institution or treatment. The differences discussed concern populations and systems, not allegations about the safety of a particular company or product. Regulators support clinical substitution with legally authorised generics in most common circumstances. This article concerns differences in the maturity of methods and manufacturing processes between dosage forms. Starting, adjusting or stopping treatment must be decided by the clinician responsible for your care.

About the data in this article: all technical parameters, regulatory documents and event timelines are drawn from publicly issued national standards, regulatory documents, pharmacopoeial chapters, professional journals and public reports. Specifically, the proportions of poorly soluble drugs are estimates repeatedly cited in review literature, not regulatory statistics; definitions differ, and the estimates illustrate frequency rather than establish a precise conclusion. Published research comparing dissolution profiles of modified-release generics and originators is limited; the multi-manufacturer nifedipine findings come from one Chinese-journal study and cannot be extrapolated to other medicines. Public statistics on rejections for failed release profiles were not found, as explicitly stated. No authoritative quantitative data were found on domestic supply proportions for advanced functional excipients, and no inference is made. Official channels disagree on some publication and public-notice dates, as marked where relevant. Where a source was not found within this search's scope, that absence is explicitly stated rather than filled with speculation.

The case analyses illustrate general manufacturing and methodological principles, not any marketed product. If your medicine's effects change, you feel unwell or have any unusual reaction, seek timely care. Starting, adjusting or stopping treatment must be decided by your treating clinician; professional medical assessment takes precedence. Do not use this article to self-medicate, stop or change medicines, switch manufacturers or adjust doses.

SOURCE NOTES

Read the source material

The original archive manuscript is restored above. These additional references offer context; their inclusion does not constitute medical validation of every original claim. Clinical and regional terminology review are pending.

GINGERA / COMMUNITY

A good question starts a conversation.

Explore a related editorial discussion. Reading is open to everyone; posting and replying require a free reader account.

Create a free accountDiscuss care across borders